Oscar Insurance GLP-1 Coverage 2026: Ozempic, Wegovy, and Mounjaro

Last Updated: January 2026

The landscape of GLP-1 medication coverage for weight loss is complex and constantly evolving, with insurers like Oscar adapting their policies. In the pivotal STEP 1 clinical trial, semaglutide 2.4 mg once weekly, marketed as Wegovy, demonstrated a mean change in body weight of 14.9% from baseline to week 68, compared with 2.4% for placebo, underscoring the medication’s efficacy for chronic weight management (New England Journal of Medicine, 2021). Despite such evidence, securing coverage for these potent drugs from private insurers like Oscar often hinges on specific FDA approvals, an individual’s medical profile, and the particular plan’s formulary. For 2026, Oscar Insurance’s stance on covering GLP-1 medications like Ozempic, Wegovy, Mounjaro, and Zepbound for weight loss demands careful examination.

The Shifting Landscape of GLP-1 Coverage in 2026

Glucagon-like peptide-1 (GLP-1) receptor agonists, and the newer dual GIP/GLP-1 agonists, have revolutionized treatment for type 2 diabetes and chronic weight management. However, their high cost—often exceeding $1,000 per month without insurance—makes coverage critical. The key distinction for insurers lies in the medication’s FDA-approved indication.

• Ozempic (semaglutide) and Mounjaro (tirzepatide): These are FDA-approved for the treatment of type 2 diabetes mellitus. While they lead to significant weight loss as a side effect, their primary approval is not for weight management alone.
• Wegovy (semaglutide) and Zepbound (tirzepatide): These formulations are specifically FDA-approved for chronic weight management in adults with obesity (BMI ≥30 kg/m²) or overweight (BMI ≥27 kg/m²) with at least one weight-related comorbidity.

A significant development impacting coverage occurred in March 2024, when the FDA approved Wegovy to reduce the risk of major adverse cardiovascular events (MACE) in adults with established cardiovascular disease and either obesity or overweight. “This approval is based on the SELECT trial, which demonstrated a significant reduction in major adverse cardiovascular events in adults with established cardiovascular disease and either overweight or obesity,” as stated by the FDA. This expanded indication for Wegovy now broadens the scope of potential coverage, especially for Medicare Part D plans and potentially private insurers like Oscar, by linking weight management directly to a critical cardiovascular health outcome.

Does Oscar Insurance Cover GLP-1 Medications for Weight Loss?

Oscar Insurance, like most commercial payers, bases its coverage decisions on several factors, predominantly FDA-approved indications and medical necessity criteria. For 2026, Oscar’s approach to GLP-1s for weight loss will likely follow these established patterns:

Ozempic (Semaglutide) and Mounjaro (Tirzepatide)

Oscar Insurance will primarily cover Ozempic and Mounjaro when prescribed for their FDA-approved indication: type 2 diabetes. Coverage typically requires a documented diagnosis of type 2 diabetes, often with a history of elevated A1C levels (e.g., ≥6.5%).

• For Weight Loss (Off-label): Coverage for these medications for weight loss alone, without a type 2 diabetes diagnosis, is highly improbable under most Oscar plans. Insurers generally do not cover off-label uses unless specific exceptions or policy riders are in place, which is rare for weight loss. Patients whose providers prescribe Ozempic or Mounjaro primarily for weight loss without a T2D diagnosis should anticipate denial.

Wegovy (Semaglutide) and Zepbound (Tirzepatide)

As the FDA-approved medications specifically for chronic weight management, Wegovy and Zepbound have a higher likelihood of Oscar coverage for weight loss. However, this coverage is almost universally subject to stringent prior authorization (PA) criteria. The March 2024 FDA approval of Wegovy for cardiovascular risk reduction provides another pathway for coverage.

• For Chronic Weight Management: Oscar plans that include weight loss medication benefits will likely cover Wegovy and Zepbound if the patient meets specific criteria:
  • BMI Thresholds: Typically, a Body Mass Index (BMI) of ≥30 kg/m² (obesity) or ≥27 kg/m² (overweight) with at least one weight-related comorbidity (e.g., hypertension, dyslipidemia, obstructive sleep apnea, type 2 diabetes).
  • Lifestyle Intervention: Documentation of participation in a supervised diet and exercise program for a specified period (e.g., 3-6 months) with inadequate weight loss results.
  • No Contraindications: Absence of contraindications such as a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
• For Cardiovascular Risk Reduction: For Wegovy specifically, Oscar may cover it for patients with established cardiovascular disease and a BMI indicative of overweight or obesity (≥27 kg/m²), following the FDA’s expanded indication. This is a critical development that could significantly increase access for a defined patient population.

Crucial Caveat: Coverage varies significantly by individual Oscar plan and whether the employer or group has chosen to include weight loss benefits. Some plans explicitly exclude weight loss medications from their benefits. Patients must verify their specific plan’s formulary and benefits document for accurate information.

Oscar’s Prior Authorization (PA) Process for GLP-1s

Prior authorization is a mandatory step for nearly all GLP-1 medications, especially when prescribed for weight loss. This process requires your healthcare provider to submit specific documentation to Oscar demonstrating that you meet their medical necessity criteria.

Common Prior Authorization Requirements:

1. Diagnosis: Clear documentation of obesity (BMI ≥30 kg/m²) or overweight (BMI ≥27 kg/m²) with specific weight-related comorbidities. For Ozempic/Mounjaro, a confirmed type 2 diabetes diagnosis is required. For Wegovy’s cardiovascular indication, documentation of established CVD and overweight/obesity is necessary.
2. BMI Calculation: Recent height and weight